JP2002527459A5 - - Google Patents

Download PDF

Info

Publication number
JP2002527459A5
JP2002527459A5 JP2000576801A JP2000576801A JP2002527459A5 JP 2002527459 A5 JP2002527459 A5 JP 2002527459A5 JP 2000576801 A JP2000576801 A JP 2000576801A JP 2000576801 A JP2000576801 A JP 2000576801A JP 2002527459 A5 JP2002527459 A5 JP 2002527459A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000576801A
Other languages
Japanese (ja)
Other versions
JP2002527459A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/024546 external-priority patent/WO2000023023A1/en
Publication of JP2002527459A publication Critical patent/JP2002527459A/ja
Publication of JP2002527459A5 publication Critical patent/JP2002527459A5/ja
Pending legal-status Critical Current

Links

JP2000576801A 1998-10-20 1999-10-20 粘膜表面を水和する方法 Pending JP2002527459A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10499998P 1998-10-20 1998-10-20
US60/104,999 1998-10-20
PCT/US1999/024546 WO2000023023A1 (en) 1998-10-20 1999-10-20 Methods of hydrating mucosal surfaces

Publications (2)

Publication Number Publication Date
JP2002527459A JP2002527459A (ja) 2002-08-27
JP2002527459A5 true JP2002527459A5 (https=) 2005-12-22

Family

ID=22303527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000576801A Pending JP2002527459A (ja) 1998-10-20 1999-10-20 粘膜表面を水和する方法

Country Status (8)

Country Link
US (2) US6264975B1 (https=)
EP (1) EP1143896B1 (https=)
JP (1) JP2002527459A (https=)
AT (1) ATE347880T1 (https=)
AU (1) AU757139B2 (https=)
CA (1) CA2346656A1 (https=)
DE (1) DE69934435T2 (https=)
WO (1) WO2000023023A1 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1143896B1 (en) * 1998-10-20 2006-12-13 The University of North Carolina at Chapel Hill Methods of hydrating the nasal mucosal surface
JP4969002B2 (ja) * 1999-06-08 2012-07-04 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン ｒＡＡＶ形質導入を増加するための化合物および方法
HK1047091B (en) * 1999-07-19 2008-07-04 University Of North Carolina At Chapel Hill Pharmacologically active compounds with two covalently linked active principles (sodium channel blocker/p2y2 receptor agonist) for the treatment of mucosal surfaces
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
WO2003038089A1 (fr) * 2001-11-02 2003-05-08 Ngk Insulators, Ltd. Compositions de solution de sonde, puce reactive faisant appel auxdites compositions et son procede de production
JP2005532254A (ja) * 2001-11-06 2005-10-27 インスパイアー ファーマシューティカルズ，インコーポレイティド 炎症性疾患を治療又は予防する方法
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
US20040152880A1 (en) * 2002-11-22 2004-08-05 Carnegie Mellon University Compositions and methods for the reversible capture of biomolecules
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
GB0303506D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
AU2004227358B8 (en) * 2003-03-31 2009-12-10 Targeted Genetics Corporation Compounds and methods to enhance rAAV transduction
AU2004266704B2 (en) 2003-08-18 2012-02-23 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US20050090505A1 (en) * 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
WO2005097087A2 (en) * 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
MXPA06011420A (es) * 2004-04-01 2007-04-20 Cardiome Pharma Corp Compuestos pegilados de modulacion de canal de iones.
CA2561819A1 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
US7705036B2 (en) 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
WO2006016530A1 (ja) 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
CA2575670A1 (en) * 2004-08-18 2006-03-02 Michael R. Johnson Aliphatic amide & ester pyrazinoylguanidine sodium channel blockers
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
US8692002B2 (en) 2004-11-18 2014-04-08 Cardiome Pharma Corp. Synthetic process for aminocyclohexyl ether compounds
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
MX2007016248A (es) 2005-06-15 2008-03-07 Cardiome Pharma Corp Procedimiento sintetico para la preparacion de compuestos de eter aminociclohexilico.
WO2007127464A2 (en) * 2006-04-28 2007-11-08 University Of Iowa Research Foundation Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection, method to identify a viral receptor or co-receptor
TW200819430A (en) * 2006-09-07 2008-05-01 Michael R Johnson Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
AU2007294547A1 (en) * 2006-09-07 2008-03-13 Parion Sciences, Inc. Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
US8337817B2 (en) 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
FI119513B (fi) 2007-03-07 2008-12-15 Dextech Medical Ab Muokatut hydroksipolymeerikonjugaatit, joilla on tappava vaikutus tuumorisoluihin
US8551534B2 (en) 2007-10-10 2013-10-08 Parion Sciences, Inc. Inhaled hypertonic saline delivered by a heated nasal cannula
WO2009139948A1 (en) 2008-02-26 2009-11-19 Johnson Michael R Poly aromatic sodium channel blockers
EP2274018B1 (en) * 2008-04-07 2013-12-18 Dextech Medical AB Modified hydroxypolymer conjugates with bone-seeking and tumor-killing moieties
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
US8778383B2 (en) 2011-06-07 2014-07-15 Parion Sciences, Inc. Methods of treatment
HUE032851T2 (en) 2011-06-27 2017-11-28 Parion Sciences Inc A chemically and metabolically stable dipeptide having strong sodium channel blocking activity
AR086745A1 (es) * 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013162771A1 (en) * 2012-04-23 2013-10-31 Massachusetts Institute Of Technology Lectin conjugates for mucin hydration
MX2014014648A (es) 2012-05-29 2015-09-04 Parion Sciences Inc Aminoamidas tipo dendrimero que poseen actividad bloqueadora del canal de sodio para el tratamiento de ojo reseco y otras enfermedades mucosas.
RU2018138195A (ru) 2012-12-17 2018-12-18 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
SG10201708931XA (en) 2012-12-17 2017-12-28 Parion Sciences Inc Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2015168574A1 (en) * 2014-05-02 2015-11-05 The Board Of Trustees Of The Leland Stanford Junior University Epithelial ion channel (enac) blockers to treat psoriasis
US9675667B2 (en) 2015-02-10 2017-06-13 Massachusetts Institute Of Technology Isolated mucins and different microorganisms, and methods of use
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
CA3016985C (en) 2016-03-07 2023-07-04 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
WO2017205739A1 (en) 2016-05-26 2017-11-30 University Of Iowa Research Foundation cis AND trans REQUIREMENTS FOR TERMINAL RESOLUTION OF HUMAN BOCAVIRUS 1
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
WO2018212846A1 (en) * 2017-05-19 2018-11-22 Ocugen, Inc. Ophthalmic compositions and methods of use
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
US12582730B2 (en) 2020-04-13 2026-03-24 Mayo Foundation For Medical Education And Research Electroporation devices and methods
US20220047686A1 (en) * 2020-08-14 2022-02-17 Mayo Foundation For Medical Education And Research Methods for treating infectious diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE639386A (https=) * 1962-10-30
JPS6034925B2 (ja) 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
JPS6032714A (ja) 1983-08-01 1985-02-19 Teijin Ltd 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
US4950591A (en) * 1987-08-14 1990-08-21 Cherksey Bruce D Membrane Na+ channel protein and related therapeutic compounds
US4894376A (en) 1988-02-26 1990-01-16 Trustees Of The University Of Pennsylvania Methods of treating diseases characterized by hyperexcitability of neurons
WO1989010369A1 (en) * 1988-04-28 1989-11-02 Schering Corporation Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
GB2237510B (en) * 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
ATE290864T1 (de) * 1993-03-26 2005-04-15 Franciscus Wilhelmus He Merkus Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotamin
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
GB9506382D0 (en) * 1995-03-29 1995-05-17 Boots Co Plc Pharmaceutical compositions
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
WO1998013001A1 (en) * 1996-09-27 1998-04-02 Nastech Pharmaceutical Company, Inc. Intranasal formulations for promoting sleep and method of using the same
EP1143896B1 (en) * 1998-10-20 2006-12-13 The University of North Carolina at Chapel Hill Methods of hydrating the nasal mucosal surface

Similar Documents

Publication Publication Date Title
BE2018C020I2 (https=)
BE2015C057I2 (https=)
BE2016C007I2 (https=)
BE2015C018I2 (https=)
BE2014C017I2 (https=)
BE2013C051I2 (https=)
BE2013C020I2 (https=)
BE2013C015I2 (https=)
BE2013C001I2 (https=)
BE2012C036I2 (https=)
BE2008C046I2 (https=)
BE2010C011I2 (https=)
JP2002509270A5 (https=)
JP2002528213A5 (https=)
BRPI0017527B8 (https=)
JP2002520779A5 (https=)
JP2002502711A5 (https=)
BE2008C047I2 (https=)
BE2011C004I2 (https=)
JP2002527129A5 (https=)
BRPI0001672A2 (https=)
JP2002528236A5 (https=)
JP2002527459A5 (https=)
BRPI0001542A2 (https=)
JP2002528339A5 (https=)